

Topical Collection

Research on Monoclonal Antibodies and Antibody Engineering

Message from the Collection Editor

Our Special Issue, “Passive Immune Prophylaxis and Therapy”, focuses on passive immune prophylaxis and therapy using monoclonal antibodies (mAbs) for a variety of diseases. As you well know, current mAb-based products have attracted much attention for being one of the most effective molecular target drugs, and have also financially succeeded in developed markets. However, several obstacles hinder the widespread use of antibody drugs, such as a high production cost, the necessity of weekly or biweekly infusions due to short half-life (approximately 20 days), quality control, laborious development of the effective mAbs, shedding the target, antigenic variations and unwanted side effects. To address the above problems, and to share your interesting knowledge in the field of passive immunization, we are inviting you to submit original research or review to this Special Issue on one of the following topics: (i) The methods of administration; (ii) Antibody engineering; (iii) How to develop the effective mAbs; (iv) Prophylactic or therapeutic mAb against virus. We are looking forward to your interesting manuscript.

Collection Editor

Dr. Tatsuya Yamazaki

Department of Microbiology and Immunology, School of Medicine, Aichi Medical University, Aichi 480-1195, Japan



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/58213

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).